Skip to content

Ascension® Humeral Resurfacing Arthroplasty (HRA) Follow-Up Study

Ascension® Humeral Resurfacing Arthroplasty HRA Follow-Up Study

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02369497
Acronym
HRA
Enrollment
59
Registered
2015-02-24
Start date
2007-12-31
Completion date
2014-07-31
Last updated
2015-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthritis

Brief summary

This is a prospective study on the Ascension HRA device to collect data to assess the safety and effectiveness of the HRA.

Detailed description

This study protocol will provide guidance to investigators wanting to perform a non-randomized, consecutive enrollment, 10-year follow-up study of patients who are treated with the Ascension® HRA. Its purpose is to measure and document the outcomes associated with implanting the Ascension HRA prosthesis. Patients will be periodically assessed to collect data related to safety and effectiveness endpoints at the following intervals: preoperative, surgery/immediate post-op, 3 months, 6 months, 1 year, 2 year, 5 year, and 10 years.

Interventions

DEVICEHRA

Humeral head resurfacing with the HRA device

Sponsors

Integra LifeSciences Corporation
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

Any patient who is to be treated with the Ascension HRA is eligible for inclusion in this study. Therefore, Principal Investigators should attempt to recruit all patients at the study site who are treated with the Ascension HRA The following patient will be included in the study - Patient who: * Is treated with the Ascension HRA * Is disabled by either non-inflammatory or inflammatory arthritis (i.e. rheumatoid arthritis, osteoarthritis and avascular necrosis * Has mild or moderate humeral head deformity and /or limited motion * Has post-traumatic arthritis * Has an intact or reparable rotator cuff * Has the means and ability to return for all required study visits * Is willing to participate in the study * Has signed an Informed Consent Form * Is at least 18 years of age and skeletally mature at the time of surgery * Is less than 75 years of age at the time of surgery

Exclusion criteria

* Infection, sepsis, and osteomyelitis * Osteoporosis * Metabolic disorders which may impair bone formation * Osteomalacia * Rapid joint destruction, marked bone loss or bone resorption apparent on X-ray * Revision procedures where other devices or treatments have failed * Refuses to be in the study; or does not have the means and ability to return for all required study visits * Currently participating in another clinical study

Design outcomes

Primary

MeasureTime frameDescription
American Shoulder and Elbow Surgeons (ASES) Score2 yearsThe American Shoulder and Elbow Score is a functional outcome tool that has been validated for various shoulder conditions

Secondary

MeasureTime frameDescription
Range of Motion2 yearsAssessment of range of motion in the shoulder
Visual Analog Scale for pain2 yearsPatient assessed score of pain in the shoulder
X-rays2 yearsX-rays are conducted to assess the location and placement of the HRA device in the shoulder
Adverse eventsSurgery; 3 month, 6 month, 1 year and 2 years post-opassessment of any adverse events that occur during the trial

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026